Huifeng Niu

Title: Huifeng Niu: Innovator in Cancer Treatment

Introduction

Huifeng Niu is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment, holding 2 patents that focus on innovative methods for addressing cancer based on genetic factors.

Latest Patents

His latest patents include groundbreaking methods for cancer treatment. The first patent discusses cancer treatment methods based on TP53 mutation status and hypermutation. This disclosure relates to methods useful for determining whether to treat cancer in a patient and involves administering a therapeutically effective amount of Compound 1 and/or its tautomers or a pharmaceutically acceptable salt or hydrate thereof. The second patent outlines a combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase. This patent discloses methods for treating proliferative disorders, particularly cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred mTORC1/2 inhibitors include MLN0128, while the preferred Aurora A kinase inhibitor of the combination is MLN8237.

Career Highlights

Throughout his career, Huifeng Niu has worked with notable companies in the pharmaceutical industry. He has been associated with Millennium Pharmaceuticals Limited and Takeda Pharmaceutical Company Limited, where he contributed to the development of innovative cancer therapies.

Collaborations

Some of his notable coworkers include Rachael L Brake and Akihiro Ohashi, who have collaborated with him on various projects in the field of cancer research.

Conclusion

Huifeng Niu's work in cancer treatment showcases his dedication to advancing medical science through innovation. His patents reflect a commitment to improving patient outcomes and addressing complex health challenges.